Natus Medical (BABY) versus Its Peers Head-To-Head Analysis
Natus Medical (NASDAQ: BABY) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its competitors? We will compare Natus Medical to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.
This is a summary of current ratings for Natus Medical and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Natus Medical Competitors||258||1823||3275||105||2.59|
Natus Medical presently has a consensus price target of $48.00, indicating a potential upside of 19.40%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 8.30%. Given Natus Medical’s higher probable upside, analysts clearly believe Natus Medical is more favorable than its competitors.
Insider and Institutional Ownership
94.6% of Natus Medical shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 5.5% of Natus Medical shares are held by company insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Natus Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Natus Medical Competitors||-327.96%||-35.81%||-12.51%|
Risk & Volatility
Natus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Natus Medical’s competitors have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.
Valuation & Earnings
This table compares Natus Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Natus Medical||$445.49 million||$48.00 million||70.53|
|Natus Medical Competitors||$2.02 billion||$430.73 million||-67.50|
Natus Medical’s competitors have higher revenue and earnings than Natus Medical. Natus Medical is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Natus Medical beats its competitors on 7 of the 13 factors compared.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.